All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-06-06T13:20:32.000Z

ASCO 2019 | Discussion: Intensive treatment strategies: at what stage should these be deployed in SMM and NDMM?

Bookmark this article

During ASCO 2019, Chicago, US, the Multiple Myeloma Hub were delighted to speak to both Maria-Victoria Mateos and Francesca Gay about the use of intensive treatment strategies in smoldering multiple myeloma (SMM) and newly diagnosed multiple myeloma (NDMM). This is the first expert discussion the MM Hub have presented, on an important and prevalent topic in myeloma. This discussion centres around the available data and both speaker's expert opinions on how the different approaches may impact on clinical practice.

The following questions are addressed:

  • Will carfilzomib + lenalidomide + dexamethasone (KRd) become a standard of care for NDMM?
  • Should KRd be utilized in asymptomatic myeloma patients (high-risk SMM)?
  • As the responses to KRd +/- autologous transplant are the same in asymptomatic high-risk SMM and NDMM, should we deploy these strategies earlier?
  • How do we identify patients with high-risk SMM?
  • Can this definition be implemented easily into clinical practice?
  • Can we avoid over-treating patients?
  • How could the KRd regimen be intensified for the treatment of NDMM?

Conclusion

Both experts agreed that intensive treatments are feasible for patients with NDMM and high-risk SMM, but this is only the starting point to personalizing therapy. The intensive treatment should be modified according to risk factors, ensuring a different, but appropriate treatment for each patient.

Intensive treatment strategies: at what stage should these be deployed in SMM and NDMM?

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox